Literature DB >> 33165325

Establishing a Competing Risk Regression Nomogram Model for Survival Data.

Lunpo Wu1, Chenyang Ge2, Hongjuan Zheng3, Haiping Lin4, Wei Fu5, Jianfei Fu6.   

Abstract

The Kaplan-Meier method and Cox proportional hazards regression model are the most common analyses in the survival framework. These are relatively easy to apply and interpret and can be depicted visually. However, when competing events (e.g., cardiovascular and cerebrovascular accidents, treatment-related deaths, traffic accidents) are present, the standard survival methods should be applied with caution, and real-world data cannot be correctly interpreted. It may be desirable to distinguish different kinds of events that may lead to the failure and treat them differently in the analysis. Here, the methods focus on using the competing regression model to identify significant prognostic factors or risk factors when competing events are present. Additionally, nomograms based on a proportional hazard regression model and a competing regression model are established to help clinicians make individual assessments and risk stratifications in order to explain the impact of controversial factors on prognosis.

Entities:  

Mesh:

Year:  2020        PMID: 33165325     DOI: 10.3791/60684

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  2 in total

1.  Characteristics, Prognosis, and Competing Risk Nomograms of Cutaneous Malignant Melanoma: Evidence for Pigmentary Disorders.

Authors:  Zichao Li; Xinrui Li; Xiaowei Yi; Tian Li; Xingning Huang; Xiaoya Ren; Tianyuan Ma; Kun Li; Hanfeng Guo; Shengxiu Chen; Yao Ma; Lei Shang; Baoqiang Song; Dahai Hu
Journal:  Front Oncol       Date:  2022-06-01       Impact factor: 5.738

2.  Predictive and Prognostic Assessment Models for Tumor Deposit in Colorectal Cancer Patients With No Distant Metastasis.

Authors:  Jingyu Chen; Zizhen Zhang; Jiaojiao Ni; Jiawei Sun; Wenhao Ren; Yan Shen; Liuhong Shi; Meng Xue
Journal:  Front Oncol       Date:  2022-02-16       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.